Quantcast

Latest Boehringer Ingelheim Stories

2014-05-28 08:31:29

RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa® (dabigatran etexilate mesylate) in the amount of $650 million. "Time and again, the benefits and safety of PRADAXA have been confirmed," said Desiree Ralls-Morrison, senior vice president and general counsel, Boehringer Ingelheim USA Corporation. "BI stands resolutely behind PRADAXA and...

2014-05-28 08:30:28

BEDFORD, Ohio, May 28, 2014 /PRNewswire/ -- Ben Venue Laboratories. Inc. ("Ben Venue"), a member of the Boehringer Ingelheim Group of Companies, announced today that the company has signed an asset purchase agreement for the sale of the assets of Bedford Laboratories, Ben Venue's U.S. injectable generics business to Hikma Pharmaceuticals PLC ("Hikma"). Bedford Laboratories is a leading provider of generic sterile injectable medicines in the U.S., with a focus on acute-care hospitals,...

2014-05-23 08:23:45

European Commission approves third product from the Boehringer Ingelheim and Lilly Diabetes alliance RIDGEFIELD, Conn. and INDIANAPOLIS, May 23, 2014 /PRNewswire/ -- The European Commission granted marketing authorization for Jardiance(®) (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company...

2014-05-18 16:20:52

-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS(TM) trials (INPULSIS(TM)-1 and -2; NCT01335464 and NCT01335477), which were published online today in the New England Journal of Medicine (NEJM). The INPULSIS(TM) trials evaluated the efficacy and safety of nintedanib, an investigational therapy being studied in people with...

2014-05-15 12:36:22

RIDGEFIELD, Conn. and INDIANAPOLIS, May 15, 2014 /PRNewswire/ -- Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announced. Additionally, similar proportions of patients in...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-29 16:29:38

DUBLIN, Apr. 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/557vt9/life_sciences_bpo) has announced the addition of the "Life Sciences BPO Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)...

2014-04-29 12:29:33

NEW YORK, April 29, 2014 /PRNewswire/ -- Auge Reichenberg, one of the most respected creative executives in healthcare communications, is joining McCann HumanCare, the consumer-focused health & wellness agency of McCann Health, as EVP, Executive Creative Director, effective April 28. Reichenberg joins from Rosetta Digital Marketing where she also held the post of Executive CD. Jeremy Perrott, Chief Creative Officer of McCann Health, and the inaugural President of the Pharma...

2014-04-17 08:28:00

RIDGEFIELD, Conn., April 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Volasertib is currently being evaluated in a Phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy....

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'